Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9520

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 6,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 120
States / cities: Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen; Drug · Biological
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 185
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more

Conditions: Multiple Myeloma
Interventions: Talquetamab, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 8 more

Conditions: Obsessive-Compulsive Disorder (OCD)
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Solid Tumor
Interventions: BG-75098, BGB-43395, Fulvestrant; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo; Biological · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 17,797 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 142
States / cities: Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more

Conditions: Overweight, Obesity
Interventions: zenagamtide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 36 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Placebo; Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 119 more

Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions: Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 6,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 181
States / cities: Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more

Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions: AR882 50 mg, AR882 75 mg, Placebo; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 83
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 74 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, mRNA-1283, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Acceptance and Commitment Therapy for Religious OCD

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)